Skip to main content

Advertisement

SpringerLink
Log in

Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

There is substantial evidence implicating the urokinase system in tissue remodeling during neo-vascularization, inflammation, tumor invasion, and metastasis. Regulated degradation of the extracellular matrix at the leading edge of migrating cells, mediated by uPA and uPAR, is required for tissue remodeling, invasiveness, and angiogenesis. Psoriasis and basal cell carcinoma (BCC) are the most common skin diseases. Pathogenesis of both of them is associated with keratinocyte hyperproliferation, inflammatory cell migration, and angiogenesis—processes in which the plasminogen system (uPA, uPAR, tPA, and PAI-1) plays a crucial role. In the present study, the comparative analysis of uPA, uPAR, tPA, and PAI-1 expression in the normal skin, in the biopsies of patients with psoriasis vulgaris, and BCC was carried out. uPA, uPAR, and PAI-1 expression was up-regulated in the epidermis of psoriatic skin and in tumor cells in BCC. Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in BCC. Increased expression of uPA in epidermal cells in psoriasis and in tumor cells in BCC suggests an important role of the uPA system for aggressively proliferating and invading cells of epidermal origin. A possible activation of the stroma, as a result of uPA–uPAR interaction between tumor cells and the surrounding stroma, is suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Al-Horani RA (2014) Serpin regulation of fibrinolytic system; implications for applications in cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 12(2):91–125

    Article  CAS  PubMed  Google Scholar 

  2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activation system in cancer metastasis; a review. Int J Cancer 72:1–22

    Article  CAS  PubMed  Google Scholar 

  3. Barker JNWN (1991) Pathophysiology of psoriasis. Lancet 338:227–230

    Article  CAS  PubMed  Google Scholar 

  4. Bhushan M, Mclaughlin B, Weiss JB (1999) Level of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054–1060

    Article  CAS  PubMed  Google Scholar 

  5. Blasi F, Vassalli J-D, Dano K (1987) Urokinase-type plasminogen activator; proenzyme, receptor, and inhibitors. J Cell Biol 104:801–804

    Article  CAS  PubMed  Google Scholar 

  6. Blasi F, Carmeliet P (2002) uPAR; a versatile signaling orchestrator. Nat Rev Mol Cell Biol 3:932–943

    Article  CAS  PubMed  Google Scholar 

  7. Blasi F, Sidenius N (2010) The urokinase receptor; focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584(9):1923–1930

    Article  CAS  PubMed  Google Scholar 

  8. Buo L, Meling GI, Karlsrud TS (1995) Antigen level of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 26:1133–1138

    Article  CAS  PubMed  Google Scholar 

  9. Chen CS, Jensen PJ (1996) Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. J Investig Dermatol 106(2):238–242

    Article  CAS  PubMed  Google Scholar 

  10. Choi J, Koo JY (2003) Quality of life issues in psoriasis. J Am Acad Dermatol 49:57–61

    Article  Google Scholar 

  11. Collen D (1999) The plasminogen (fibrinolytic) system. Thromb Haemost 82(2):259–270

    CAS  PubMed  Google Scholar 

  12. Collen D (2001) Role of the plasminogen system in fibrin-homeostasis and tissue remodelling. Hematology 1(1):1–9

    Article  Google Scholar 

  13. Colman RW, Wu Y, Liu Y (2010) Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signaling. Thromb Haemost 104:875–885

    Article  CAS  PubMed  Google Scholar 

  14. Creamer D, Allen M, Sousa A (1995) Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 147:1661–1667

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Creamer D, Jaggar M, Allen M (1997) Overexpression of angiogenic growth factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137:8851–8855

    Article  Google Scholar 

  16. Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236

    Article  CAS  PubMed  Google Scholar 

  17. Detmar M, Brown LF, Claffey KP (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 180:1141–1146

    Article  CAS  PubMed  Google Scholar 

  18. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16(4):428

    Article  PubMed  PubMed Central  Google Scholar 

  19. Elder JT, Fisher GJ, Lindquist PB (1989) Overexpression of transforming growth factor-a in psoriatic epidermis. Science 243:811–814

    Article  CAS  PubMed  Google Scholar 

  20. Ettehadi P, Greaves MW, Wallach D (1994) Elevated tumor necrosis factor-a (TNF-a) biological activity in psoriatic lesions. Clin Exp Immunol 96:146–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Feller L, Khammissa RA, Kramer B, Altini M, Lemmer J (2016) Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med 12:11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fraki JE, Lazarus GS, Gilgor RS, Marchase P, Singer KH (1983) Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 108:39–44

    Article  CAS  PubMed  Google Scholar 

  23. Ganzetti G, Campanati A, Molinelli E, Offidani A (2016) Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol 8(2):120–131

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gilhar A, David M, Kalish RS, Weisinger G (1996) In vivo effects of cytokines on psoriatic skin grafted on nude mice; involvement of the tumour necrosis factor (TNF) receptor. Clin Exp Immunol 106(1):134–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gissler HM, Frank R, Kramer MD (1993) Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Br J Dermatol 128(6):612–618

    Article  CAS  PubMed  Google Scholar 

  26. Godi A (2004) New approaches to psoriasis treatment. Acta Dermatovenerol 13(2):50–57

    Google Scholar 

  27. Gramling MW, Church FC (2010) Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 125:377–381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Grondahl-Hansen J, Nielsen LS, Kristensen P, Grondahl-Hansen V, Andreasen PA, Dano K (1985) Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 113(3):257–263

    Article  CAS  PubMed  Google Scholar 

  29. Grondahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristensen P, Frentz G, Dano K (1987) Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Investig Dermatol 88(1):28–32

    Article  CAS  PubMed  Google Scholar 

  30. Harbeck N, Kates RE, Schmitt M (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352

    Article  CAS  PubMed  Google Scholar 

  31. Heissig B, Dhahri D, Eiamboonsert S, Salama Y, Shimazu H, Munakata S, Hattori K (2015) Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell Mol Life Sci 72(24):4759–4770

    Article  CAS  PubMed  Google Scholar 

  32. Hildenbrand R, Schaaf A (2009) The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 34(1):15–23

    CAS  PubMed  Google Scholar 

  33. Hohler T, Marker-Hermann E (2001) Psoriatic arthritis; clinical aspects, genetics and the role of T-cells. Curr Opin Rheumatol 13:273–279

    Article  CAS  PubMed  Google Scholar 

  34. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS (1988) Epidermal plasminogen activator is abnormal in cutaneous lesions. J Investig Dermatol 90(6):777–782

    Article  CAS  PubMed  Google Scholar 

  35. Jensen PJ, Baird J, Belin D, Vassalli JD, Busso N, Gubler P, Lazarus GS (1990) Tissue plasminogen activator in psoriasis. J Investig Dermatol 95(5):13–14

    Article  Google Scholar 

  36. Kauvar AN, Cronin T Jr, Roenigk R, Hruza G, Bennett R (2015) Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 41(5):550–571

    Article  CAS  PubMed  Google Scholar 

  37. Kuroda K, Sapadin A, Shoji T (2001) Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Investig Dermatol 116:713–720

    Article  CAS  PubMed  Google Scholar 

  38. Lanoue J, Goldenberg G (2016) Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthet Dermatol 9(5):26–36

    PubMed  PubMed Central  Google Scholar 

  39. Leurer C, Rabbani SA (2015) Plasminogen activator system—diagnostic, prognostic and therapeutic implications in breast cancer, a concise review of molecular pathology of breast cancer. In: Gunduz M (ed) A concise review of molecular pathology of breast cancer. ISBN 978-953-51-2030-8

  40. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166(5):1069–1080

    Article  CAS  PubMed  Google Scholar 

  41. Lotti T, Bonan P, Panconesi E (1989) Plasminogen activation in psoriasis. Acta Derm Venereol Suppl (Stockh) 146:36–38

    CAS  Google Scholar 

  42. Lotti T, Bonan P, Cannarozzo G, Fedi AM, Panconesi E (1990) Antipsoriatic therapies inhibit epidermal plasminogen activator activity. Int J Dermatol 29(7):528–530

    Article  CAS  PubMed  Google Scholar 

  43. Lupu M, Caruntu C, Ghita MA, Voiculescu V, Voiculescu S, Rosca AE, Caruntu A, Moraru L, Popa IM, Calenic B, Greabu M, Costea DE (2016) Gene expression and proteome analysis as sources of biomarkers in basal cell carcinoma. Dis Mark. doi:10.1155/2016/9831237

    Google Scholar 

  44. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ (1994) Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101(2):105–112

    Article  CAS  PubMed  Google Scholar 

  45. Maguire T, Chin D, Soutar D, Duffy MJ (2000) Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. Int J Cancer 85:457–459

    Article  CAS  PubMed  Google Scholar 

  46. Mazar AP, Henkin J, Goldfarb RH (1999) The urokinase plasminogen activator system in cancer; implication for tumor angiogenesis and metastasis. Angiogenesis 3:15–32

    Article  CAS  PubMed  Google Scholar 

  47. Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D’Alessio S (2015) Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of notch. Cancer Res 75(22):4895–4909

    Article  CAS  PubMed  Google Scholar 

  48. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS (1992) Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Investig Dermatol 98(3):351–358

    Article  CAS  PubMed  Google Scholar 

  49. Nagy B, Ban J, Brdar B (1977) Fibrinolysis associated with human neoplasia; production of plasminogen activators by human tumors. Int J Cancer 19:614–620

    Article  CAS  PubMed  Google Scholar 

  50. Nickoloff BJ, Mitra RS, Varani J (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820–828

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Nickoloff BJ (2000) Characterization of lymphocyte-dependent angiogenesis using a SCID mouse; Human skin model of psoriasis. J Investig Dermatol 5:67–73

    Article  CAS  Google Scholar 

  52. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brunner N, Petersen LJ, Kristensen JK (2002) Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51(11):563–567

    Article  CAS  PubMed  Google Scholar 

  53. Parfyonova YV, Plekhanova OS, Tkachuk VA (2002) Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Moscow) 67(1):139–156

    Article  Google Scholar 

  54. Plekhanova OS, Parfenova EV, Tkachuk VA (2015) Mechanisms of vascular remodeling following arterial injury. Kardiologiia 55(7):63–77

    Article  CAS  PubMed  Google Scholar 

  55. Quinn AG, Perkins W (2010) Non-melanoma skin cancer and other epidermal skin tumors. In: Burns T, Breathnach S, Cox N, Griffiths C (eds) Rook’s textbook of dermatology. Blackwell Publishing Ltd, Chichester

    Google Scholar 

  56. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2012) Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population. JAMA Dermatol 151(10):1081–1086

    Article  Google Scholar 

  57. Rox JM, Reinartz J, Kramer MD (1996) Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). Arch Dermatol Res 288(9):554–558

    Article  CAS  PubMed  Google Scholar 

  58. Ruano J, Suárez-Fariñas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG (2016) Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PloS One 11(2):1–18

    Article  Google Scholar 

  59. Santibanez JF (2013) Transforming growth factor-beta and urokinase-type plasminogen activator; dangerous partners in tumorigenesis. implications in skin cancer volume. Hindawi Publishing Corporation, UK, ISRN Dermatology. Article ID 597927

    Google Scholar 

  60. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Investig 88(4):1073–1079

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Schmitt M, Harbeck N, Thompson C (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis; prognostic relevance and target for therapy. Thromb Hemost 78(1):285–296

    CAS  Google Scholar 

  62. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A (2010) Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 10(8):1051–1067

    Article  CAS  PubMed  Google Scholar 

  63. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL (2003) Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82(3):184–193

    Article  CAS  PubMed  Google Scholar 

  64. Spiers EM, Lazarus GS, Lyons-Giordano B (1994) Expression of plasminogen activator enzymes in psoriatic epidermis. J Investig Dermatol 102(3):333–338

    Article  CAS  PubMed  Google Scholar 

  65. Spiers EM, Lazarus GS, Lyons-Giordano B (1996) Expression of plasminogen activators in basal cell carcinoma. J Pathol 178:290–296

    Article  CAS  PubMed  Google Scholar 

  66. Teofoli P, Mancini A, Lotti T (1996) Cyclosporine A inhibits tPA mRNA transcription in A431 cell line. Skin Pharmacol 9(2):137–140

    Article  CAS  PubMed  Google Scholar 

  67. Tkachuk VA, Plekhanova OS, Beloglazova IB, Parfenova EV (2013) A role of multi-domain structure of urokinase in regulating vascular growth and remodeling. Ukr Biokhim Zh 85:18–45

    CAS  Google Scholar 

  68. Tsuboi R, Yamaguchi T, Kurita Y, Nakao H, Ishihara K (1988) Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis. J Investig Dermatol 90:869–872

    Article  CAS  PubMed  Google Scholar 

  69. Tutrone WD, Saini R, Weinberg JM (2004) Biological therapy for psoriasis; an overview of infliximab, etanercept, efalizumab and alefacept. I Drugs 7(1):45–49

    CAS  PubMed  Google Scholar 

  70. Vassalli J-D (1994) The urokinase receptor. Fibrinolysis 8(1):172–181

    Article  CAS  Google Scholar 

  71. Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O’Halloran TV, Lengyel E (2013) Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther 12(12):2628–2639

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Source of funding: Grant (No. 14-24-00086) of the Russian Science Foundation. The authors acknowledge that the work was carried out using equipment purchased with the funding from the Program of Development of M. V. Lomonosov Moscow State University.

Author information

Authors and Affiliations

  1. Lomonosov Moscow State University, 31-5, Lomonosovsky av., Moscow, 119192, Russia

    K. A. Rubina, V. Yu. Sysoeva, M. I. Kurdina & V. A. Tkachuk

  2. Russian Cardiology Research Center, 3-rd Cherepkovskaya, 15a, Moscow, Moscow, 121552, Russia

    E. I. Zagorujko, Z. I. Tsokolaeva, Ye. V. Parfyonova & V. A. Tkachuk

Authors
  1. K. A. Rubina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Yu. Sysoeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. I. Zagorujko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z. I. Tsokolaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. I. Kurdina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ye. V. Parfyonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. A. Tkachuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. A. Rubina.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Bioethical Committee of Russian Cardiology Research Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rubina, K.A., Sysoeva, V.Y., Zagorujko, E.I. et al. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Arch Dermatol Res 309, 433–442 (2017). https://doi.org/10.1007/s00403-017-1738-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-017-1738-z

Keywords

Search

Navigation